| 000 | 01439 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250513140017.0 | ||
| 264 | 0 | _c19980514 | |
| 008 | 199805s 0 0 eng d | ||
| 022 | _a0960-8931 | ||
| 024 | 7 |
_a10.1097/00008390-199802000-00014 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCascinelli, N | |
| 245 | 0 | 0 |
_aEvaluation of clinical efficacy and tolerability of intravenous high dose thymopentin in advanced melanoma patients. _h[electronic resource] |
| 260 |
_bMelanoma research _cFeb 1998 |
||
| 300 |
_a83-9 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAdjuvants, Immunologic _xadministration & dosage |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunophenotyping |
| 650 | 0 | 4 | _aInjections, Intravenous |
| 650 | 0 | 4 |
_aLymphocytes, Tumor-Infiltrating _xpathology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMelanoma _ximmunology |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aSkin Neoplasms _ximmunology |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 |
_aThymopentin _xadministration & dosage |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aBelli, F | |
| 700 | 1 | _aMascheroni, L | |
| 700 | 1 | _aLenisa, L | |
| 700 | 1 | _aClemente, C | |
| 773 | 0 |
_tMelanoma research _gvol. 8 _gno. 1 _gp. 83-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/00008390-199802000-00014 _zAvailable from publisher's website |
| 999 |
_c9476202 _d9476202 |
||